Date: November 13, 2026

To,

National Stock Exchange of India Limited,
Exchange Plaza, C-1, Block G,
Bandra Kurla Complex, Bandra (E),
Mumbai – 400 051
NSE Scrip Symbol: MANIPALHOS

BSE Limited,
20th Floor, P.J. Towers,
Dalal Street,
Mumbai - 400001.
BSE Scrip Code: 544847

Subject: Press Release and Investor Presentation for the Earnings Conference Call with Analysts and Investors of Manipal Health Enterprises Limited (the "Company")

Dear Sir/Ma'am,

Pursuant to Regulation 30 and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), please find enclosed the Press Release and Investor Presentation in connection with the earnings conference call scheduled to be held today i.e., November 13, 2026, to discuss the Unaudited (Standalone and Consolidated) Financial Results of the Company for the quarter and half year ended September 30, 2026.

The above announcements will also be uploaded on the website of the Company and can be accessed using the link: https://www.manipalhospitals.com/mhel-financial-reports#investor-earnings-call

This intimation is being submitted for your information and records.

Thank you.

For Manipal Health Enterprises Limited
(formerly Manipal Health Enterprises Private Limited)

SATHISH KOLAR RAMAMOORTHY
Digitally signed by SATHISH KOLAR RAMAMOORTHY
Date: 2026.11.13 15:55:14 +05'30'

Sathish K R
Company Secretary and Compliance Officer
Membership No.: A15203

Manipal Hospitals Delivers 37.3% Revenue Growth in Q2 FY27, EBITDA Rises 29.8%.
Patient-led growth momentum support performance across the network

Bengaluru, Karnataka, November 13, 2026: Manipal Health Enterprises Limited (Manipal Hospitals), India's largest pan-India multi-specialty hospital networks by bed capacity, today announced its financial results for the quarter ended September 30, 2026 (Q2 FY27).

The company delivered a strong operating performance during the quarter, supported by sustained patient demand, growth in high-acuity specialties and capacity absorption. Improving occupancy and operating efficiencies further strengthened the performance of the expanded network.

Operating Performance

Revenue from operations stood at ₹ 3,399 crore in Q2 FY27, registering 37.3% year-on-year growth, while EBITDA stood at ₹ 882 crore, up 29.8% year-on-year. EBITDA margin was 26.0%, and 26.8% excluding Sahyadri. For H1 FY27, revenue reached ₹ 6,490 crore, up 37.7%, and EBITDA reached ₹ 1,631 crore, up 28.2%. Excluding the ₹ 15 crore one-off gain in H1 FY26, EBITDA growth was 29.8%. Sahyadri, acquired on October 3, 2025, is included in the current-period consolidated results but not in the corresponding prior-year periods.

Inpatient volumes grew 35.0% to approximately 169,000 and outpatient volumes rose 27.2% to approximately 1.74 million during Q2 FY27. Occupancy improved by 160 basis points year-on-year to 70.1%, with average operational capacity of 7,331 beds and average length of stay of 2.8 days. The 300-licensed-bed Electronic City hospital in Bengaluru opened during the quarter, taking the network's licensed bed capacity to 13,440 as of September 30, 2026.

Reported PAT stood at ₹ 285 crore in Q2 FY27. PAT excluding exceptional items was ₹ 380 crore, up 21.6% year-on-year; additionally excluding ₹ 75 crore of post-tax interest on the NCD raised for the Sahyadri acquisition, PAT was ₹ 455 crore, up 45.6%. Consolidated ARPOB stood at ₹ 70,600 per day; excluding Sahyadri, ARPOB was ₹ 76,600 per day, up 8.5%. Net debt, excluding lease liabilities, stood at ₹ 343 crore at quarter-end, with net debt to annualised EBITDA of 0.10 times.

Sahyadri Integration Supports Growth

Sahyadri Hospitals contributed ₹ 375 crore in revenue and ₹ 73 crore in EBITDA during Q2 FY27. For H1 FY27, revenue reached ₹ 707 crore, up 17.8%*, and EBITDA reached ₹ 131 crore, up 24.1%*. H1 occupancy was 67.0%, up 270 basis points, while ARPOB increased 12.5% to ₹ 44,100 per day.

Integration progressed through the rollout of centralised procurement rates and the addition and enhancement of clinical capability & programs. Digital revenue contribution at Sahyadri reached 11%, supported by continued digital engagement and community outreach initiatives. The phased brand transition has been initiated with a Q4 FY27 timeline, while the nine-hospital Pune cluster is being developed as an integrated network with shared leadership, referrals and clinical capabilities.

High-Acuity Specialties Continue to Drive Momentum

The six CONGO-R Centres of Excellence—Cardiac Sciences, Oncology, Neurosciences, Gastroenterology, Orthopedics and Renal Sciences—continued to support high-acuity care across the network. In H1 FY27, oncology revenue grew 51% year-on-year, neurosciences 47% and orthopedics

44%, with cardiac sciences, gastroenterology and renal sciences growing 39%, 36% and 38%, respectively. These consolidated growth rates reflect the expanded network as well as operating performance. Investments during the half year included advanced oncology equipment at Nashik, an AI-assisted neuro biplane cath lab at Mukundpur, orthopedic robots at Patiala, Vijayawada and Pune Baner, and an AI-enabled cath lab at Old Airport Road.

Performance Highlights:

Particulars (₹ Cr)	Q2 FY27	Q2 FY26	YoY	Q1 FY27	QoQ	H1 FY27	H1 FY26	YoY
Revenue from Operations	3,399.4	2,475.4	37.3%	3,090.6	10.0%	6,490.0	4,713.1	37.7%
EBITDA	882.2	679.8	29.8%	749.0	17.8%	1,631.2	1,272.4	28.2%
EBITDA Margin %	26.0%	27.5%	-150 bps	24.2%	180 bps	25.1%	27.0%	-190 bps
PAT (excluding Exceptions)	380.2	312.7	21.6%	258.9	46.7%	639.1	585.1	9.2%
PAT Margin % (Ex-Exceptions)	11.2%	12.6%	-140 bps	8.4%	280 bps	9.8%	12.4%	-260 bps
ARPOB (₹/day)	70,600	70,600	0.0%	71,500	-1.3%	71,100	70,800	0.4%
Occupancy %	70.1%	68.5%	160 bps	65.0%	510 bps	67.6%	65.3%	230 bps

Notes: EBITDA excludes other income and ESOP expenses. H1 FY26 EBITDA includes a one-off gain of ₹ 15 crore; excluding this, H1 FY27 EBITDA growth was 29.8%. PAT and PAT margin in the table are reported figures excluding exceptional items. PAT including exceptional items was ₹ 285.0 crore in Q2 FY27, ₹ 317.8 crore in Q2 FY26, ₹ 243.4 crore in Q1 FY27, ₹ 528.4 crore in H1 FY27 and ₹ 571.8 crore in H1 FY26. Additionally excluding post-tax Sahyadri acquisition NCD interest of ₹ 75 crore in Q2 FY27 and ₹ 165 crore in H1 FY27, PAT was approximately ₹ 455 crore and ₹ 804 crore, respectively, up 45.6% and 37.4% year-on-year. ARPOB in the table is consolidated and rounded to the nearest ₹ 100; excluding Sahyadri, Q2 and H1 FY27 ARPOB was ₹ 76,600 and ₹ 76,900 per day, up 8.5% and 8.6%, respectively. Changes in margins and occupancy are expressed in basis points using the displayed rounded percentages; Current-period consolidated results include Sahyadri; corresponding prior-year consolidated periods do not.

Commenting on the Q2 FY27 performance, Dilip Jose, Managing Director & CEO, Manipal Hospitals, said:

"We are pleased that our performance this quarter has been driven by volumes with more patients accessing our care and this we believe is the sustainable option for growth in care delivery. Improved capacity utilisation, particularly in high-acuity specialties continued to be a key driver while maintaining focus on strengthening our clinical capabilities, improving operational performance and building a more integrated healthcare platform."

About Manipal Hospitals:

Manipal Hospitals is one of India's leading integrated healthcare providers serving ~ 8 million patients annually, focussed on providing accessible, high-quality healthcare services. Manipal's integrated network today has a Pan-India footprint of 50 hospitals with over 13,400 licensed beds across 14 States & Union Territories. The network is India's largest multispecialty hospital network by bed capacity, supported by a talented pool of 11,000+ doctors and an employee strength of over 25,000.

With a commitment to provide patient-centric care, Manipal Hospitals combines clinical expertise with advanced technology, research and innovation to serve a multitude of patients across the globe. Its continued focus on clinical quality and operational excellence is reflected in its NABH accreditation, with several of its hospitals also accredited by NABL and recognised for its excellence in nursing and emergency care. For more information, please visit - https://www.manipalhospitals.com/

Manipal Health Enterprises Limited
98, HAL Old Airport Rd, Kodihalli
Bengaluru, Karnataka 560017, India

Manipal Health Enterprises Limited

Earnings Update: Q2 FY27

manipalhospitals

LIFE'S ON

Disclaimer

This presentation is issued by Manipal Health Enterprises Limited (the "Company") for general information purposes only, without regards to the specific objectives, financial situation or requirements of any particular person. This presentation may not be copied, published, distributed or transmitted, in whole or in part, for any purpose, and should not be construed as legal, tax, investment or other advice.

This presentation does not constitute a prospectus, placement document, offering circular or offering memorandum and is not an offer or invitation or recommendation or solicitation or inducement to buy or sell any equity shares or other securities of the Company or its Subsidiaries. This presentation shall not form the basis of, or be relied on, in connection with, any contract or investment decision in relation to any securities.

Unless otherwise stated, the information contained herein is based on management information and estimates. The information contained herein is only current as of the date specified herein, has not been independently verified and may be subject to change without notice. Please note that past performance is not indicative of future results. Please note that the recipient will not be updated in the event the information becomes stale. The Company assumes no responsibility to publicly amend, modify or revise any forward-looking statements, on the basis of any subsequent development, information or events, or otherwise. The Company as such, makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of the content including any information or opinions contained herein. Any opinions expressed in this presentation or the contents of this presentation are subject to change without notice. Neither the delivery of this presentation nor any further discussions of the Company with any of the recipients shall, under any circumstances, create any implication that there has been no change in the affairs of the Company since the date of this presentation.

This presentation also contains forward-looking statements based on the currently held beliefs, opinions and assumptions of the Company. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance, or achievements of the Company or industry results, to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements. Given these risks, uncertainties and other factors, our occupiers and the Indian and global economies, recipients of this presentation are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments or the impact of events which cannot currently be ascertained. In addition to statements which are forward looking by reason of context, the words 'may', 'will', 'should', 'expects', 'plans', 'intends', 'anticipates', 'believes', 'estimates', 'predicts', 'potential' or 'continue' and similar expressions identify forward-looking statements.

Certain information (including any guidance and proforma information) presented herein is based on management information, assumptions and estimates and is not audited or reviewed by an auditor or based on GAAP, Ind AS or any other internationally accepted accounting principles. The reader should not consider such items as an alternative to the historical financial results or other indicators of the Company's profit, cash flows or distribution based on any GAAP.

Disclaimer

Actual results may be materially different from the expectations expressed or implied by this information, and there can be no assurance that the expectations reflected in this information will prove to be correct.

By reading this presentation the recipient acknowledges that the recipient will be solely responsible for its own investigation, assessment and analysis of the market and the market position of the Company and that the recipient will conduct its own analysis and be solely responsible for forming its own view of the potential future performance of the business of the Company. This presentation may not be all inclusive and may not contain all of the information that the recipient considers material. The distribution of this presentation in certain jurisdictions may be restricted by law. Accordingly, any persons in possession of this presentation should inform themselves about and observe any such restrictions.

None of the Company or any of their respective affiliates, advisers or representatives accept any liability whatsoever for any loss howsoever arising from any information presented or contained in this presentation. Furthermore, no person is authorized to give any information or make any representation which is not contained in, or is inconsistent with, this presentation. Any such extraneous or inconsistent information or representation, if given or made, should not be relied upon as having being authorized by or on behalf of the Company.

Investors are advised to consult their investment advisor before making an investment decision. This information should not be used or considered as financial or investment advice, recommendation or an offer for sale or a solicitation of any offer to buy any equity shares or other securities of the Company. This presentation and any of its contents do not provide for and should not be construed as any assurance or guarantee of returns or distribution to investors or the trading price of the securities.


THIS PRESENTATION DOES NOT CONSTITUTE OR FORM ANY PART OF ANY OFFER, INVITATION OR RECOMMENDATION TO PURCHASE OR SUBSCRIBE FOR ANY SHARES OR OTHER SECURITIES IN INDIA, THE UNITED STATES OR ELSEWHERE.

Table of Contents

I	Q2 FY27 Performance Highlights
II	H1 FY27 Performance Highlights
III	Other Updates
IV	Annexures

Pan India Hospital Network: 13,440 Licensed Beds

Network as of Sep 30, 2026



O&M Hospitals, which are hospitals that the group operates and manages pursuant to operation & management agreements

Key regions

Bed mix by Region

- Karnataka (20 Hospitals | 6,704 Beds) Owned: 3,419; O&M: 3,285
- West Bengal, Odisha, Jharkhand, and Sikkim (East India) (10 Hospitals | 2,887 Beds) Owned: 2,387; O&M:500
- Maharashtra & Goa (13 Hospitals | Owned: 2,291 Beds)
- Others (7 Hospitals | 1,558 Beds)

Leading Presence Across 3 Metros

Bengaluru	→	13 Hospitals | 2,879 Beds
Kolkata	→	5 Hospitals | 1,513 Beds
Pune	→	9 Hospitals | 1,284 Beds

Bed Split (Owned vs O&M)

Owned : 9,655[1]

Operational : 7,331

O&M : 3,785

Balanced Presence across Metro & Non-metros

Metro	**Non-Metro**
30 Hospitals | **6,399** Beds	**20** Hospitals | **7,041** Beds
Owned: 6,399	Owned: 3,256
O&M Beds: Nil	O&M Beds: 3,785

1) Also includes three hospitals operated pursuant to a joint management and collaboration agreement, a concession agreement and a memorandum of understanding and management agreement with Human Care Medical Charitable Trust ("HCMCT"), Eastern India Health Foundation ("EIHF") and Konkan Mitra Mandal Medical Trust ("KMMMT"), respectively

Q2 FY27 Performance Highlights



Manipal Hospital @ Electronic City, Bengaluru (300 Licensed Beds)
Launched in Q2 FY27

manipalhospitals
LIFE'S ON

Executive Summary



Financial Metrics

Revenue: INR 3,399 Cr
(+37.3%[1] vs Q2FY26)

EBITDA: INR 882 Cr
(+29.8%[2] vs Q2FY26)

EBITDA Margin: 26.0%
(Ex-Sahyadri: 26.8%)

PAT: INR 380 Cr.[3]
(+21.6% vs Q2FY26)
(INR 455 Cr. Ex-NCD int.[4], +45.6% vs Q2FY26)



Operational Metrics

IP Volumes: 169k
(+35.0%[5] vs Q2FY26)

Occupancy: 70.1%
(+160 bps vs Q2FY26)

ALOS: 2.8 Days

ARPOB[6]: INR 70,600 / day
(INR 76,600/day, +8.5% Ex-Sahyadri)


CONGO-R Mix: 63.1%

1. Q2FY27 includes Sahyadri revenue of INR 375 Cr.
2. Q2FY27 includes Sahyadri EBITDA of INR 73 Cr.
3. PAT excludes exceptional items (INR 95 Cr. in Q2FY27).
4. Sahyadri NCD interest impact (net off tax) is INR 75 Cr.
5. Q2FY27 includes Sahyadri IP volume of 29k.
6. Rounded off to the nearest 100.


* Sahaydri was acquired on October 3, 2025 and hence Q2FY26 numbers do not include Sahyadri.
EBTIDA excludes other income and ESOP expenses.

Financial Highlights


Revenue (INR Cr.)




EBITDA (INR Cr.) and EBITDA Margin



PAT (INR Cr.) and PAT Margin[1]




Net Debt (INR Cr.) and Net Debt / EBITDA[3]




1. PAT excludes exceptional items.
2. Sahyadri NCD interest impact net off tax is INR 75 Cr. in Q2FY27.
3. Net Debt excludes lease liabilities. Net Debt / EBITDA on annualized basis.

Operational Highlights


of Operational Beds[1]




Occupied beds & Occupancy %




IP Volumes (in 000s)




ARPOB (INR k/day)



ALOS (Days)




OP Volumes (in 000s)



1. Average for that period.

H1 FY27 Performance Highlights



Janakpuri West, Delhi Metro Station

manipalhospitals
LIFE'S ON

Executive Summary



Financial Metrics

Revenue: INR 6,490 Cr
(+37.7%[1] vs H1FY26)

EBITDA: INR 1,631 Cr
(+28.2%[2] vs H1FY26,
+29.8% ex-one-off[3])

EBITDA Margin: 25.1%
(Ex-Sahyadri: 25.9%)

PAT: INR 639 Cr.[4]
(+9.2% vs H1FY26)
(INR 804 Cr Ex-NCD int.[5], +37.4% vs H1FY26)



Operational Metrics

IP Volumes: 325k
(+36.8%[6] vs H1FY26)

Occupancy: 67.6%
(+230 bps vs H1FY26)

ALOS: 2.8 Days

ARPOB[7]: INR 71,100 / day
(INR 76,900/day, +8.6% Ex-Sahyadri)


CONGO-R Mix: 64.2%

1. H1FY27 includes Sahyadri revenue of INR 707 Cr.
2. H1FY27 includes Sahyadri EBITDA of INR 131 Cr.
3. H1FY26 includes one-off gain of INR 15 Cr.
4. PAT excludes exceptional items. (INR 110 Cr. in H1FY27).
5. Sahyadri NCD interest impact (net off tax) is INR 165 Cr. in H1FY27.
6. H1FY27 includes Sahyadri IP volume of 55k
7. Rounded off to the nearest 100.


* Sahaydri was acquired on October 3, 2025 and hence H1FY26 numbers do not include Sahyadri.

Financial Highlights


Revenue (INR Cr.)



EBITDA (INR Cr.) and EBITDA Margin




PAT (INR Cr.) and PAT Margin[2]




1. Excludes one-off gain in H1FY26 of INR 15 Cr.
2. PAT excludes exceptional items.
3. Excludes Sahyadri NCD interest of INR 165 Cr. net off tax in H1FY27.

Operational Highlights


of Operational Beds[1]




Occupied beds & Occupancy %




IP Volumes (in 000s)




ARPOB (INR k/day)



ALOS (Days)




OP Volumes (in 000s)



1. Average for that period.

CONGO-R Specialties



Centre of Excellence	Cardiac	Onco	Neuro	Gastro	Ortho	Renal
Growth (y-o-y)	39%	51%	47%	36%	44%	38%

Other Updates

manipalhospitals
LIFE'S ON

Advanced Clinical Equipment Delivering Excellence at Scale

Advanced Medical Infrastructure that Enables Tertiary and Quaternary Care across Our Network[1]...

19 LINACs[2]	**16** PET CTs	**2** Tomotherapy Units	**27** Orthopedic & Spine Surgical Robots
59 Cath Labs	**44** MRI[3]	**24** Soft Tissue Robots	**6** Gamma Cameras



Radixact Tomotherapy



LINAC



Elekta Evo Linac



J&J Ortho Robot



Da Vinci Xi Soft Tissue Robot




Intravascular Ultrasound (IVUS)

H1 FY27 Additions



High end LINAC and PET CT @ MH Nashik



AI-assisted Neuro biplane Cath Lab system @ MH Mukundpur



Orthopedic Robo @ MH Patiala, MH Vijayawada and MH Pune Baner



AI enabled Cath Lab(Allia, GE USA) at Old Airport Road

1) Across the network, including O&M hospitals
2) Linear Accelerators
3) Magnetic Resonance Imaging

Clinical Highlights

1. MH Dhakuria pioneered a **first-of-its-kind Laser-guided renal artery angioplasty in Eastern India region** on a 60-year-old

2. MH Broadway successfully excised a **growing 10 × 10 × 10 cm neck lymphangioma compressing the airway** and closely involving major blood vessels and nerves

3. MH Electronic City performed an advanced treatment on a 61-year-old for a **brain tumour located deep within brain's sensory cortex** with **South India's first reported use of 5-ALA fluorescence guided surgery**

4. MH Kanakapura performed its **first Bentall procedure (aortic root and valve replacement)**

5. MH Goa performed **Goa's first covered self-expandable metallic stent procedure** to treat critical airway blockage and tracheoesophageal fistula caused by esophageal tumour

6. MH Patiala becomes the **first hospital in the city to introduce advanced Robot-Assisted Orthopedic Surgery**

7. MH Deccan Gymkhana performed a **complex Balloon Pulmonary Valvotomy** to fix congenital pulmonary valve stenosis on a **2-month-old baby**

8. MH Sarjapur hosted **India's First dedicated Adaptive Deep Brain Stimulation (DBS) summit,** showcasing the future of Parkinson's care & other movement disorders



Manipal Hospital Dhakuria Successfully Treats 42-Year-Old Patient with Life-Threatening Ruptured Brain Aneurysm

Kolkata | BR Team

The neurosurgery team at Manipal Hospital, Dhakuria has successfully treated a 42-year-old farmer, Mr. Ramesh Kumar (name changed), from Bihar, who arrived at the hospital with a life-threatening brain haemorrhage caused by a ruptured anterior communicating artery (ACOM) aneurysm. ACOM is a weak, balloon-like bulge in a blood vessel connecting the two main arteries supplying the front part of the brain.

The patient was initially presented with severe headache, repeated vomiting and drowsiness. Imaging tests subsequently confirmed bleeding around the brain caused by a ruptured aneurysm, medically known as aneurysmal subarachnoid haemorrhage (SAH). Given the seriousness of the condition and the risk of re-bleeding, the team led by Dr. Nirup Dutta, Consultant - Neurosurgery, Manipal Hospital, Dhakuria, decided that urgent surgical intervention was necessary to secure the aneurysm.

Mr. Ramesh had no previous diagnosis of a brain aneurysm, which can remain undetected for years without causing any noticeable symptoms. A CT scan confirmed bleeding around the brain, while a further specialized test called Digital Subtraction Angiography (DSA), which provides detailed images of the blood vessels in the brain, revealed a complex, wide-neck aneurysm measuring approximately 8.9 × 3 mm in the anterior communicating artery. The aneurysm also had a hypoplastic left A1 segment, meaning one of the blood vessels supplying the area was smaller than usual, making the procedure more challenging and requiring careful surgical planning. A brain aneurysm is a weak, balloon-like bulge in the wall of a blood vessel that can remain silent until it ruptures. Once it bursts, it can cause bleeding around the brain and become life-threatening. Following the first bleed, the risk of bleeding again is particularly high during the first 48-96 hours. A second bleed can be much more dangerous and may lead to severe brain damage or even death. According to the treating doctor, around 50-70% of patients may not survive a second bleed, making it extremely important to treat a ruptured aneurysm as quickly as possible. A ruptured aneurysm can also lead to complications such as vasospasm, a narrowing of the blood vessels that can reduce blood flow to the brain and potentially cause another stroke.

The doctors performed a specialized procedure known as microsurgical clipping to secure the ruptured aneurysm and prevent it from bleeding again. The patient underwent a left pterional craniotomy, a surgical approach that involves opening a small part of the skull to reach the affected area of the brain. The aneurysm was then carefully identified and clipped to stop blood from entering the weakened portion of the blood vessel. While both surgical clipping and endovascular coiling are established treatments for brain aneurysms, the choice depends on the patient's condition and the size, location and shape of the aneurysm.



94-year-old stroke patient treated successfully by hosp

TIMES NEWS NETWORK

Mangaluru: KMC Hospital Mangaluru successfully treated a 94-year-old woman who suffered an acute ischemic stroke, enabling her to regain mobility and return home with a good recovery.

The elderly patient was brought to the hospital within 30 minutes of developing sudden weakness on the left side of her body, a classic warning sign of stroke. Recognizing the emergency, the hospital's stroke team immediately initiated evaluation under the leadership of Dr Rohit Pai, consultant neurologist, and Dr Keerthiraj B, interventional neuroradiologist. An MRI scan of the brain confirmed an acute ischemic stroke caused by a blockage in the right middle cerebral artery (MCA), one of the brain's major arteries responsible for supplying blood to areas that control movement, sensation, and speech.

To identify the exact location and extent of the blockage, the team performed digital subtraction angiography (DSA), an advanced imaging procedure that provides detailed pictures of the blood vessels. The scan revealed a clot completely blocking the right internal carotid artery, the main artery supplying blood to the brain, with the blockage extending into the middle cerebral artery. This significantly reduced blood flow to a large portion of the brain and required immediate intervention. Following prompt consent from the patient's family, the multidisciplinary stroke team performed an emergency mechanical thrombectomy within an hour of her arrival.

The minimally invasive procedure involved navigating a catheter through a blood vessel to the blocked artery in the brain to remove the clot and restore blood flow. The patient recovered remarkably well after the procedure, and by the time of discharge, was able to walk with support, showing significant improvement from the paralysis caused by the stroke. Dr Rohit Pai said, "Stroke is a medical emergency where every minute matters. Age alone should never prevent patients from receiving advanced stroke treatment. Early hospital arrival, rapid diagnosis, and timely intervention can significantly improve recovery, as demonstrated by this patient's excellent outcome."

Sahyadri Update

Integration Vectors	Update
Procurement Synergies	• Centralized procurement rates rolled out
Clinical Talent	• Addition (83) & Inter-operability of clinicians (58) • Enhance clinical capability & programs
Marketing/Digital	• Continued focus on key digital revenue initiatives • Digital revenue contribution: 11% • Drive outreach programs to enhance neighbourhood connect

Re-branding	• Brand transition process initiated: Phased approach
	  • Timeline: Q4 FY27
	  • Engage with Government agencies

H1FY27 Metrics

Revenue: INR 707 Cr
(+17.8% vs H1FY26[1], Q2-o-Q1: +13%)

EBITDA: INR 131 Cr
(+24.1% vs H1FY26[1], Q2-o-Q1:+26%)

EBITDA Margin: 18.5%
Q1 vs Q2: 17.5% to 19.5%

Occupancy: 67.0%
(+270 bps vs H1FY26[1])

ARPOB: INR 44,100 / day
(+12.5% vs H1FY26[1])

1) H1FY26 as per erstwhile management reporting since Sahyadri was acquired on October 3, 2025.

Region Wise Metrics

Karnataka Region




Particulars	Q2 FY26	Q2 FY27
Revenue	1,221	1,495
Operational Beds	2,028	2,366
Occupancy %	67.0%	66.5%
IP Volumes (‘000s)	48	55

Maharashtra + Goa Region

Particulars	Q2 FY26	Q2 FY27
Revenue	153	574
Operational Beds	352	1,751
Occupancy %	65.5%	69.8%
IP Volume (‘000s)	8	39

East India Region



Particulars	Q2 FY26	Q2 FY27
Revenue	592	692
Operational Beds	1,855	1,858
Occupancy %	69.7%	71.4%
IP Volume (‘000s)	39	38

Rest of India Region



Particulars	Q2 FY26	Q2 FY27
Revenue	449	576
Operational Beds	1,196	1,356
Occupancy %	70.0%	74.8%
IP Volume (‘000s)	30	37

Region-wise metrics are only for hospital business and excludes HealthMap revenue of INR 61 Cr. in Q2FY26 and INR 63 Cr. Q2FY27.

Thank You

manipalhospitals
LIFE'S ON

Income Statement

Particulars (INR Cr.)	Q2FY27	Q1FY27	Q2FY26	H1FY27	H1FY26	FY26
Revenue from operations	3,399.4	3,090.6	2,475.4	6,490.0	4,713.1	10,335.8
Less: Cost of materials consumed	682.9	626.1	508.9	1,309.0	965.4	2,116.2
Less: Employee benefits expense (excluding ESOP expenses)	476.4	449.6	344.1	926.0	672.2	1,457.0
Less: Other expenses	1,357.9	1,265.9	942.6	2,623.8	1,803.0	4,118.3
EBITDA	882.2	749.0	679.8	1,631.2	1,272.4	2,644.2
Less: ESOP expenses	10.2	12.4	8.2	22.6	14.3	33.0
Add: Other Income	99.7	74.6	48.0	174.3	96.3	184.8
Less: Finance costs	300.1	293.3	156.1	593.4	287.7	864.3
Less: Depreciation and amortization expense	204.9	187.3	150.9	392.1	291.5	679.6
Profit before exceptional items and tax	466.7	330.6	412.7	797.4	775.3	1,252.2
Add: Exceptional items	-95.2	-15.5	5.1	-110.6	-13.3	-74.1
Profit before tax	371.6	315.2	417.8	686.7	762.0	1,178.1
Less: Tax expense	86.6	71.8	100.0	158.3	190.2	261.5
Profit after tax	285.0	243.4	317.8	528.4	571.8	916.6
Profit after tax (excluding exceptional items)	380.2	258.9	312.7	639.1	585.1	990.7

Notes:

1. Rent reversal under Ind-AS 116 is INR 52 Cr. for Q2FY27, INR 49 Cr. for Q1FY27, INR 35 Cr. for Q2FY26, INR 69 Cr. for H1FY26 and INR 156 Cr. for FY26.
2. Interest cost on NCD taken for Sahyadri acquisition (net off tax) is INR 75 Cr. for Q2FY27 and INR 90 Cr. for Q1FY27.